Analysts forecast that PetIQ Inc (NASDAQ:PETQ) will announce earnings per share of $0.28 for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for PetIQ’s earnings, with the lowest EPS estimate coming in at $0.27 and the highest estimate coming in at $0.29. PetIQ posted earnings per share of $0.66 in the same quarter last year, which would indicate a negative year over year growth rate of 57.6%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, August 7th.
According to Zacks, analysts expect that PetIQ will report full-year earnings of $0.81 per share for the current financial year. For the next financial year, analysts expect that the company will report earnings of $0.97 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow PetIQ.
PetIQ (NASDAQ:PETQ) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.19. The company had revenue of $148.44 million during the quarter, compared to analyst estimates of $139.03 million. PetIQ had a net margin of 0.51% and a return on equity of 9.47%.
PETQ stock traded down $0.33 during trading on Monday, hitting $35.67. 297,764 shares of the stock traded hands, compared to its average volume of 412,311. PetIQ has a 1 year low of $21.29 and a 1 year high of $43.93. The stock has a 50 day simple moving average of $31.56. The stock has a market capitalization of $1.01 billion, a PE ratio of 28.54, a price-to-earnings-growth ratio of 1.95 and a beta of 2.06. The company has a current ratio of 2.89, a quick ratio of 1.51 and a debt-to-equity ratio of 0.38.
In other news, insider Will Santana sold 20,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $34.07, for a total transaction of $681,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James Nathan Clarke bought 31,031 shares of the stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $28.12 per share, with a total value of $872,591.72. The disclosure for this purchase can be found here. Over the last three months, insiders sold 120,291 shares of company stock valued at $3,575,091. 23.79% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of PETQ. Rhumbline Advisers boosted its stake in shares of PetIQ by 125.5% during the fourth quarter. Rhumbline Advisers now owns 20,239 shares of the company’s stock valued at $475,000 after purchasing an additional 11,262 shares during the period. BlackRock Inc. boosted its stake in shares of PetIQ by 46.5% during the fourth quarter. BlackRock Inc. now owns 1,343,674 shares of the company’s stock valued at $31,536,000 after purchasing an additional 426,190 shares during the period. Citigroup Inc. boosted its stake in shares of PetIQ by 43.5% during the fourth quarter. Citigroup Inc. now owns 1,827 shares of the company’s stock valued at $43,000 after purchasing an additional 554 shares during the period. Northern Trust Corp boosted its stake in shares of PetIQ by 33.4% during the fourth quarter. Northern Trust Corp now owns 197,947 shares of the company’s stock valued at $4,645,000 after purchasing an additional 49,582 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of PetIQ by 226.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 95,881 shares of the company’s stock valued at $2,250,000 after purchasing an additional 66,498 shares during the period. 91.46% of the stock is owned by hedge funds and other institutional investors.
PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.
Further Reading: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.